<DOC>
	<DOC>NCT00244114</DOC>
	<brief_summary>Based on the finding that anaphylactic reactions to Benefix ("FIX") are associated with a specific IgE, a Basophil histamine release assay was selected to evaluate and demonstrate subject sensitization to FIX.</brief_summary>
	<brief_title>Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Study Group: Written informed consent or assent, as applicable. Subjects with moderate to severe Hemophilia B (FIX:C &lt;5%), who have reported class II or class III allergic manifestations within 24 hours of a BeneFIX infusion. Control Group: Written informed consent or assent, as applicable. Subjects with moderate to severe Hemophilia B (FIX:C &lt;5%) Study group: Subjects who had no reaction when rechallenged with BeneFIX, in the absence of prophylactic immunomodulating therapy. Subjects whose most recent allergic manifestations with BeneFIX occurred &gt;36 months prior to providing written informed consent for this study. Subjects who have taken antihistamine, steroidal, or other immunosuppressive therapy within 72 hours of the scheduled visit for this study. Subjects with immune disorders. Subjects unable to comply with a minimum 5day FIX washout requirement. Control group: Subjects with documented evidence of prior allergic reaction to any FIX product. Subjects with documented evidence of prior or current FIX inhibitor (BU &gt;0.6). Subjects have taken antihistamine, steroidal, or other immunosuppressive therapy within 72 hours of the scheduled study blood draw. Subjects with immune disorder. Subjects unable to comply with a minimum 5day FIX washout requirement.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>Allergic Reaction</keyword>
</DOC>